MX2017004324A - Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías. - Google Patents

Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías.

Info

Publication number
MX2017004324A
MX2017004324A MX2017004324A MX2017004324A MX2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A
Authority
MX
Mexico
Prior art keywords
fatty acid
disease
compositions
omega
acid ester
Prior art date
Application number
MX2017004324A
Other languages
English (en)
Spanish (es)
Inventor
Thorsteinsson Thorsteinn
D Sancilio Frederick
DANIEL-ARCHIBALD Glynis
Lopez-Toledano Miguel
Abd Almalik Ahmed Mohammed Daak Ahmed
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017004324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MX2017004324A publication Critical patent/MX2017004324A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2017004324A 2014-10-10 2015-10-09 Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías. MX2017004324A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462062652P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
PCT/US2015/054933 WO2016057915A1 (fr) 2014-10-10 2015-10-09 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Publications (1)

Publication Number Publication Date
MX2017004324A true MX2017004324A (es) 2017-07-04

Family

ID=54347886

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004324A MX2017004324A (es) 2014-10-10 2015-10-09 Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías.
MX2020002238A MX2020002238A (es) 2014-10-10 2017-04-03 Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002238A MX2020002238A (es) 2014-10-10 2017-04-03 Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.

Country Status (8)

Country Link
EP (1) EP3212236A1 (fr)
BR (1) BR112017007428A2 (fr)
CA (1) CA2963952C (fr)
CL (1) CL2017000867A1 (fr)
MA (1) MA40846A (fr)
MX (2) MX2017004324A (fr)
WO (1) WO2016057915A1 (fr)
ZA (1) ZA201702385B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193563A1 (fr) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, et application et préparation pharmaceutique de cette dernière
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
MX2022001238A (es) 2019-08-13 2022-07-13 Team Foods Colombia Sa Composicion lipidica que comprende antioxidantes y polifenoles naturales como alternativa no farmacologica para el tratamiento y la prevencion de nafld.
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972063C (fr) * 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Composition auto-emulsifiante d'acide gras .omega.3
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
EP2793867B1 (fr) * 2011-12-22 2021-01-20 Baes, Erik Capsules à libération retardée de gélatine/alginate comprenant des acides gras oméga-3, et leurs procédés et leurs utilisations
MY189576A (en) * 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
EP3212236A1 (fr) 2017-09-06
CA2963952A1 (fr) 2016-04-14
WO2016057915A1 (fr) 2016-04-14
CL2017000867A1 (es) 2017-11-03
CA2963952C (fr) 2023-10-17
MX2020002238A (es) 2020-07-13
MA40846A (fr) 2017-09-05
ZA201702385B (en) 2020-12-23
BR112017007428A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
MX2020002238A (es) Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.
IN2014DN08449A (fr)
EA201890852A1 (ru) Соли валбеназина и их полиморфы
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
PH12014501750A1 (en) Pharmaceutical compositions containing dimethyl fumarate
WO2016134223A3 (fr) Dérivés d'acide nonanoïque tétrahydronaphthyridinyle fluorés et leurs utilisations
WO2015184256A3 (fr) Lipides biodégradables pour l'administration d'acides nucléiques
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
NZ596228A (en) Compositions and methods for the treatment of inflammation
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
WO2014107730A3 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
BR112016024020A8 (pt) composição farmacêutica
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
NZ702705A (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
WO2018093237A3 (fr) Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité
MY194044A (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
WO2013033602A3 (fr) Amides d'acide gras, compositions et procédés d'utilisation
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
WO2014073946A3 (fr) Utilisation des bétalaïnes et de leurs dérivés pour la préparation d'un médicament destiné au traitement, à la prévention, à la régulation et au contrôle d'hépathopathies, de pathologies associées à infiltrat inflammatoire, de nécrose et pour la modification des dépôts de lipides
WO2015123480A3 (fr) Compositions et méthodes pour prévenir et/ou traiter une schistosomiase
MX2019015712A (es) Formas cristalinas de beta-sitosterol.